An observational study in Neoplasms, Colorectal Neoplasms and Rectal Diseases, sponsored by Royal Marsden NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
This study tests biopsy and tissue from patients who have been treated for primary rectal cancer at the Royal Marsden Hospital between 2011 and 2013, who have an mrTRG score at post-chemoradiotherapy MRI. It is a retrospective pilot study to determine the apoptotic and proliferative index count pre and post chemoradiotherapy.
The investigators hope to validate the apoptotic and proliferative index as a predictive response marker and lend support to mrTRG as a putative prognostic tool in the treatment pathway for rectal cancer patients. Even though this is a retrospective study, the investigators hope that pre-treatment apoptotic and proliferative scores will correlate to post treatment response and mrTRG scores. In doing so, the investigators can predict how patients will respond to treatment from initial diagnostic biopsies and foresee a patients individual treatment plan.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 148 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Royal Marsden NHS Foundation Trust is the lead sponsor of 262 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with rectal cancer, diagnosed between 2011 and 2013, who have had an mrTRG score in a post-radiotherapy MRI scan.
Exclusion Criteria:
Apoptotic index, Ki67 and Geminin in cells per mm cubed from diognostic biopsy
Tissue biopsy taken at endoscopy to confirm cancer diagnosis is studied
Time frame: Tissue removed at diagnosis (approximately 15 weeks prior to surgery)
Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour
Tissue removed during surgery (to resect tumour) is studied
Time frame: Tissue removed during operation
Time to local recurrence
Time frame: At one and three years
Disease Free Survival (DFS)
Time frame: At one and three years
Overall Survival (OS)
Time frame: At one and three years
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust